Related Experiment Video
Updated: Feb 18, 2026
10:13
Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
Published on: May 6, 2019
9.6K
S101, an Inhibitor of Proliferating T Cells, Rescues Mice From Superantigen-Induced Shock.
Alexei Shir1, Shoshana Klein1, Idit Sagiv-Barfi1
1Unit of Cellular Signaling, Silberman Life Sciences Institute, Hebrew University of Jerusalem, Safra Campus, Israel.
The Journal of Infectious Diseases
|November 18, 2017
Summary
A novel compound, S101, effectively treats toxic shock by inhibiting T-cell proliferation. This drug candidate shows significant promise for treating superantigen-induced toxic shock and related T-cell-driven diseases.
Area of Science:
- Immunology
- Pharmacology
Background:
- Superantigens (SAgs) are potent bacterial toxins causing severe immune responses like toxic shock.
- Current treatments for SAg-induced toxic shock are limited, necessitating novel therapeutic strategies.
Purpose of the Study:
- To evaluate the therapeutic potential of S101, a T-cell proliferation inhibitor, against superantigen-induced toxic shock.
- To elucidate the molecular targets and pathways affected by S101.
Main Methods:
- A severe mouse model of toxic shock was used to assess S101 efficacy.
- In vivo studies involved administering S101 before and after superantigen challenge.
- Molecular pathway analysis identified S101's targets, including the T-cell receptor and aryl hydrocarbon receptor.
Main Results:
- A single S101 injection completely rescued mice challenged with superantigens.
- S101 administration up to 2 hours post-challenge rescued 40% of mice.
- S101 was found to inhibit T-cell receptor signaling, inflammatory pathways, and the aryl hydrocarbon receptor.
Conclusions:
- S101 demonstrates significant therapeutic efficacy in a preclinical model of superantigen-induced toxic shock.
- S101's mechanism involves targeting key T-cell activation and inflammatory pathways.
- S101 represents a promising candidate for treating toxic shock and other T-cell-mediated pathologies.
